Dae-Woong Cho
Chief Executive Officer at CELLIVERY THERAPEUTICS, INC.
Net worth: 26 M $ as of 30/03/2023
Profile
Dae-Woong Cho was the founder of ProCell Therapeutics, Inc. (founded in 2005) where he held the title of President & Chief Executive Officer from 2010 to 2012.
He is also the founder of Cellivery Therapeutics, Inc. (founded in 2014) where he currently holds the titles of CEO, Director & Research Director.
Dr. Cho's former job(s) include working as a Principal at Vanderbilt University, Yuhan Corp., GenoCheck Co., Ltd., and Chonnam National University.
Dr. Cho's education history includes a doctorate degree from Vanderbilt University in 2005 and a graduate degree from Hanyang University in 1992.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
CELLIVERY THERAPEUTICS, INC.
13.40% | 29/06/2023 | 4,899,454 ( 13.40% ) | 26 M $ | 30/03/2023 |
Dae-Woong Cho active positions
| Companies | Position | Start |
|---|---|---|
| CELLIVERY THERAPEUTICS, INC. | Chief Executive Officer | 27/08/2014 |
Former positions of Dae-Woong Cho
| Companies | Position | End |
|---|---|---|
ProCell Therapeutics, Inc.
 ProCell Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ProCell Therapeutics, Inc. develops protein-based therapeutics. It handles the research and development of biotherapeutics capable of entering cells through proprietary Macromolecule Intracellcellular Transduction Technologies (MITT) using a line-up of Macromolecule Transduction Domain (MTD). The company was founded on December 12, 2005 and is headquartered in Seoul, South Korea. | Founder | - |
| Chonnam National University | Corporate Officer/Principal | - |
| YUHAN CORPORATION | Corporate Officer/Principal | - |
GenoCheck Co., Ltd.
 GenoCheck Co., Ltd. Medical SpecialtiesHealth Technology GenoCheck Co., Ltd. is a holding company, which conducts research in biotechnology and offers products and services related to genes. Its activities include exploring and testing of genes related to human diseases, developing diagnostic deoxyribonucleic acid (DNA) chip and new drugs. The firm's products include microarray, ribonucleic acid stabilization solution, and DNA extraction kit. The company was founded on May 1, 2000 and is headquartered in Seoul, South Korea. | Corporate Officer/Principal | - |
| Vanderbilt University | Corporate Officer/Principal | - |
Training of Dae-Woong Cho
| Vanderbilt University | Doctorate Degree |
| Hanyang University | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| CELLIVERY THERAPEUTICS, INC. | Health Technology |
| YUHAN CORPORATION | Health Technology |
| Private companies | 2 |
|---|---|
GenoCheck Co., Ltd.
GenoCheck Co., Ltd. Medical SpecialtiesHealth Technology GenoCheck Co., Ltd. is a holding company, which conducts research in biotechnology and offers products and services related to genes. Its activities include exploring and testing of genes related to human diseases, developing diagnostic deoxyribonucleic acid (DNA) chip and new drugs. The firm's products include microarray, ribonucleic acid stabilization solution, and DNA extraction kit. The company was founded on May 1, 2000 and is headquartered in Seoul, South Korea. | Health Technology |
ProCell Therapeutics, Inc.
ProCell Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ProCell Therapeutics, Inc. develops protein-based therapeutics. It handles the research and development of biotherapeutics capable of entering cells through proprietary Macromolecule Intracellcellular Transduction Technologies (MITT) using a line-up of Macromolecule Transduction Domain (MTD). The company was founded on December 12, 2005 and is headquartered in Seoul, South Korea. | Health Technology |
- Stock Market
- Insiders
- Dae-Woong Cho
